{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:16:13Z","timestamp":1792278973685,"version":"4.4.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"Supplement_7","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI103055"],"award-info":[{"award-number":["AI103055"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI099243"],"award-info":[{"award-number":["AI099243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A correlate of protection (CoP) is a measured adaptive immune response to vaccination or infection that is associated with protection against disease. However, the degree to which a CoP can serve as a surrogate end point for vaccine efficacy should depend on the robustness of this association. While cholera toxin is a dominant target of the human antibody response to Vibrio cholerae infection, antitoxin responses are not associated with long-term immunity, and are not effective CoPs for cholera. Instead, protection appears to be mediated by functional antibodies that target the O-polysaccharide coated V. cholerae outer membrane. Vibriocidal antibodies, which are complement-dependent bactericidal antibodies, remain the most accepted CoP for cholera and are used as surrogate end points in some vaccine studies. However, the association between vibriocidal antibody titers and immunity is not absolute, and they are unlikely to reflect a mechanistic correlate of protection against cholera.<\/jats:p>","DOI":"10.1093\/infdis\/jiab497","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T19:19:24Z","timestamp":1633029564000},"page":"S732-S737","source":"Crossref","is-referenced-by-count":20,"title":["Correlates of Protection for Cholera"],"prefix":"10.1093","volume":"224","author":[{"given":"Anita S","family":"Iyer","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason B","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"2021122015210813700_CIT0001","volume-title":"Correlates of vaccine-induced protection: methods and implications","author":"World Health Organization (WHO).","year":"2013"},{"key":"2021122015210813700_CIT0002","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination.","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"2021122015210813700_CIT0003","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination.","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2021122015210813700_CIT0004","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","article-title":"Updates on immunologic correlates of vaccine-induced protection.","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"2021122015210813700_CIT0005","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.vaccine.2017.05.005","article-title":"Correlates of protection for enteric vaccines.","volume":"35","author":"Holmgren","year":"2017","journal-title":"Vaccine"},{"key":"2021122015210813700_CIT0006","volume-title":"Ending cholera: a global roadmap to 2030","author":"Global Task Force on Cholera Control.","year":"2017"},{"key":"2021122015210813700_CIT0007","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2019.08.086","article-title":"Global oral cholera vaccine use, 2013-2018.","volume":"38","author":"Pezzoli","year":"2020","journal-title":"Vaccine"},{"key":"2021122015210813700_CIT0008","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(17)30359-6","article-title":"Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis.","volume":"17","author":"Bi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021122015210813700_CIT0009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0140-6736(05)66550-6","article-title":"Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.","volume":"366","author":"Ali","year":"2005","journal-title":"Lancet"},{"key":"2021122015210813700_CIT0010","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1473-3099(18)30465-1","article-title":"Protection of young children with cholera vaccine.","volume":"18","author":"Luquero","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021122015210813700_CIT0011","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/143.6.818","article-title":"Duration of infection-derived immunity to cholera.","volume":"143","author":"Levine","year":"1981","journal-title":"J Infect Dis"},{"key":"2021122015210813700_CIT0012","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/infdis\/jir416","article-title":"Natural cholera infection-derived immunity in an endemic setting.","volume":"204","author":"Ali","year":"2011","journal-title":"J Infect Dis"},{"key":"2021122015210813700_CIT0013","doi-asserted-by":"crossref","first-page":"PMID: 31776240","DOI":"10.1128\/mSphere.00597-19","article-title":"Vibrio cholerae at the intersection of immunity and the microbiome.","volume":"4","author":"Weil","year":"2019","journal-title":"mSphere"},{"key":"2021122015210813700_CIT0014","doi-asserted-by":"crossref","first-page":"e1004405","DOI":"10.1371\/journal.ppat.1004405","article-title":"Insights into Vibrio cholerae intestinal colonization from monitoring fluorescently labeled bacteria.","volume":"10","author":"Millet","year":"2014","journal-title":"PLoS Pathog"},{"key":"2021122015210813700_CIT0015","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00594-17","article-title":"Analysis of the human mucosal response to cholera reveals sustained activation of innate immune signaling pathways.","volume":"86","author":"Bourque","year":"2018","journal-title":"Infect Immun"},{"key":"2021122015210813700_CIT0016","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/IAI.02765-14","article-title":"Comparative proteomic analysis reveals activation of mucosal innate immune signaling pathways during cholera.","volume":"83","author":"Ellis","year":"2015","journal-title":"Infect Immun"},{"key":"2021122015210813700_CIT0017","doi-asserted-by":"crossref","first-page":"PMID: 31434744","DOI":"10.1128\/mSphere.00206-19","article-title":"Posttranslational regulation of IL-23 production distinguishes the innate immune responses to live toxigenic versus heat-inactivated Vibrio cholerae.","volume":"4","author":"Weil","year":"2019","journal-title":"mSphere"},{"key":"2021122015210813700_CIT0018","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1128\/mr.47.4.510-550.1983","article-title":"New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.","volume":"47","author":"Levine","year":"1983","journal-title":"Microbiol Rev"},{"key":"2021122015210813700_CIT0019","doi-asserted-by":"crossref","first-page":"PMID: 27999163.","DOI":"10.1128\/mBio.02021-16","article-title":"Single-cell analysis of the plasmablast response to Vibrio cholerae demonstrates expansion of cross-reactive memory B cells.","volume":"7","author":"Kauffman","year":"2016","journal-title":"MBio"},{"key":"2021122015210813700_CIT0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/infdis\/jiy414","article-title":"Cholera: immunity and prospects in vaccine development.","volume":"218","author":"Harris","year":"2018","journal-title":"J Infect Dis"},{"key":"2021122015210813700_CIT0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0035-9203(79)90119-6","article-title":"Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.","volume":"73","author":"Levine","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021122015210813700_CIT0022","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0140-6736(90)90080-O","article-title":"Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.","volume":"335","author":"Clemens","year":"1990","journal-title":"Lancet"},{"key":"2021122015210813700_CIT0023","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/infdis\/151.2.236","article-title":"Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection.","volume":"151","author":"Glass","year":"1985","journal-title":"J Infect Dis"},{"key":"2021122015210813700_CIT0024","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1371\/journal.pntd.0000221","article-title":"Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh.","volume":"2","author":"Harris","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"2021122015210813700_CIT0025","doi-asserted-by":"crossref","first-page":"e00098","DOI":"10.1128\/CVI.00098-17","article-title":"Antibody-based correlates of protection against cholera analysis of a challenge study in a cholera-naive population.","volume":"24","author":"Haney","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2021122015210813700_CIT0026","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0035-9203(94)90423-5","article-title":"Studies of infection with Vibrio cholerae O139 synonym Bengal in family contacts of index cases.","volume":"88","author":"Faruque","year":"1994","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021122015210813700_CIT0027","doi-asserted-by":"crossref","first-page":"e0006399","DOI":"10.1371\/journal.pntd.0006399","article-title":"Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh.","volume":"12","author":"Aktar","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2021122015210813700_CIT0028","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau6242","article-title":"Estimating cholera incidence with cross-sectional serology.","volume":"11","author":"Azman","year":"2019","journal-title":"Sci Transl Med"},{"key":"2021122015210813700_CIT0029","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/imr.12503","article-title":"Systems serology for evaluation of HIV vaccine trials.","volume":"275","author":"Ackerman","year":"2017","journal-title":"Immunol Rev"},{"key":"2021122015210813700_CIT0030","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1128\/CVI.00321-12","article-title":"Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.","volume":"19","author":"Johnson","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"2021122015210813700_CIT0031","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/infdis\/121.5.505","article-title":"The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement.","volume":"121","author":"Neoh","year":"1970","journal-title":"J Infect Dis"},{"key":"2021122015210813700_CIT0032","first-page":"271","article-title":"Vibriocidal titre in cholera cases and contacts: its value in assessing endemicity of or susceptibility to cholera.","volume":"39","author":"Khan","year":"1987","journal-title":"Trop Geogr Med"},{"key":"2021122015210813700_CIT0033","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/infdis\/145.4.465","article-title":"Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.","volume":"145","author":"Clements","year":"1982","journal-title":"J Infect Dis"},{"key":"2021122015210813700_CIT0034","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/infdis\/jiv108","article-title":"Immunogenicity of the bivalent oral cholera vaccine Shanchol in Haitian adults with HIV infection.","volume":"212","author":"Ivers","year":"2015","journal-title":"J Infect Dis"},{"key":"2021122015210813700_CIT0035","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1016\/j.vaccine.2021.06.034","article-title":"Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia.","volume":"39","author":"Mwaba","year":"2021","journal-title":"Vaccine"},{"key":"2021122015210813700_CIT0036","article-title":"Long-term immunogenicity of live oral cholera vaccine CVD 103-HgR in adolescents aged 12\u201317 years in the United States","author":"McCarty","journal-title":"Am J Trop Med Hyg"},{"key":"2021122015210813700_CIT0037","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12865-020-00360-1","article-title":"Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.","volume":"21","author":"Xian","year":"2020","journal-title":"BMC Immunol"},{"key":"2021122015210813700_CIT0038","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.vaccine.2019.12.034","article-title":"Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5years of age: revaccination after an interval of over three years of primary vaccination with a single dose of vaccine.","volume":"38","author":"Chowdhury","year":"2020","journal-title":"Vaccine"},{"key":"2021122015210813700_CIT0039","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1016\/j.vaccine.2018.05.102","article-title":"A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol\u00ae, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.","volume":"36","author":"Russo","year":"2018","journal-title":"Vaccine"},{"key":"2021122015210813700_CIT0040","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1086\/421275","article-title":"Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh.","volume":"189","author":"Saha","year":"2004","journal-title":"J Infect Dis"},{"key":"2021122015210813700_CIT0041","doi-asserted-by":"crossref","first-page":"e02847-20","DOI":"10.1128\/mBio.02847-20","article-title":"Humans surviving cholera develop antibodies against Vibrio cholerae O-specific polysaccharide that inhibit pathogen motility.","volume":"11","author":"Charles","year":"2020","journal-title":"mBio"},{"key":"2021122015210813700_CIT0042","doi-asserted-by":"crossref","first-page":"e00626","DOI":"10.1128\/IAI.00626-16","article-title":"Immunity provided by an outer membrane vesicle cholera vaccine is due to O-antigen-specific antibodies inhibiting bacterial motility.","volume":"85","author":"Wang","year":"2017","journal-title":"Infect Immun"},{"key":"2021122015210813700_CIT0043","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1016\/j.vaccine.2016.10.023","article-title":"A monoclonal antibody that targets the conserved core\/lipid A region of lipopolysaccharide affects motility and reduces intestinal colonization of both classical and El Tor Vibrio cholerae biotypes.","volume":"34","author":"Levinson","year":"2016","journal-title":"Vaccine"},{"key":"2021122015210813700_CIT0044","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1128\/IAI.00054-14","article-title":"Vibrio cholerae-induced inflammation in the neonatal mouse cholera model.","volume":"82","author":"Bishop","year":"2014","journal-title":"Infect Immun"},{"key":"2021122015210813700_CIT0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/imm.12861","article-title":"Prospects from systems serology research.","volume":"153","author":"Arnold","year":"2018","journal-title":"Immunology"},{"key":"2021122015210813700_CIT0046","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A functional role for antibodies in tuberculosis.","volume":"167","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"2021122015210813700_CIT0047","doi-asserted-by":"crossref","first-page":"eabb4757","DOI":"10.1126\/scitranslmed.abb4757","article-title":"Mapping functional humoral correlates of protection against malaria challenge following RTS,S\/AS01 vaccination.","volume":"12","author":"Suscovich","year":"2020","journal-title":"Sci Transl Med"},{"key":"2021122015210813700_CIT0048","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1128\/CVI.00037-12","article-title":"Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh.","volume":"19","author":"Patel","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"2021122015210813700_CIT0049","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2018.04.011","article-title":"Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.","volume":"36","author":"Haney","year":"2018","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab497\/40774194\/jiab497.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_7\/S732\/41826162\/jiab497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_7\/S732\/41826162\/jiab497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T15:22:14Z","timestamp":1640013734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/Supplement_7\/S732\/6404467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":49,"journal-issue":{"issue":"Supplement_7","published-online":{"date-parts":[[2021,10,20]]},"published-print":{"date-parts":[[2021,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab497","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,15]]},"published":{"date-parts":[[2021,10,20]]}}}